Abstract:Drug discovery starts with known function, either of a compound or a protein, in-turn prompting investigations to probe 3D structure of the compound-protein interface. As protein structure determines function, we hypothesized that unique 3D structural motifs represent primary information denoting unique function that can drive discovery of novel agents. Using a physics-based protein structure analysis platform developed by us, designed to conduct computationally intensive analysis at supercomputing speeds, we probed a high-resolution protein x-ray crystallographic library developed by us. We selected 3D structural motifs whose function was not otherwise established, that offered environments supporting binding of drug-like chemicals and were present on proteins that were not established therapeutic targets. For each of eight potential binding pockets on six different proteins we accessed a 60 million compound library and used our analysis platform to evaluate binding. Using eight-day colony formation assays acquired compounds were screened for efficacy against human breast, prostate, colon and lung cancer cells and toxicity against human bone marrow stem cells. Compounds selectively inhibiting cancer growth segregated to two pockets on separate proteins. The compound, Dxr2-017, exhibited selective activity against human melanoma cells in the NCI-60 cell line screen, had an IC50 of 19 nM against human melanoma M14 cells in our eight-day assay, while over 2100-fold higher concentrations inhibited stem cells by less than 30%. We show that Dxr2-017 induces anoikis, a unique form of programmed cell death in need of targeted therapeutics. The predicted target protein for Dxr2-017 is expressed in bacteria, not in humans. This supports our strategy of focusing on unique 3D structural motifs. It is known that functionally important 3D structures are evolutionarily conserved. Here we demonstrate proof-of-concept that protein structure represents high value primary data to support discovery of novel therapeutics. This approach is widely applicable.

Structure-based drug design: From nucleic acid to membrane protein targets

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Towards Structure-Based Protein Drug Design

Molecular docking as a popular tool in drug design, an in silico travel

Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery

Computational drug development for membrane protein targets

Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

Recent Trends in Drug Design and Discovery

Molecular Docking and Structure-Based Drug Design Strategies

Computer Modeling for Interaction of Ligands and Receptors and Their Applications in Drug Design

Structure-based drug design: NMR-based approach for ligand-protein interactions.

Protein Structure Inspired Drug Discovery

Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances

Structure-based drug design: aiming for a perfect fit

Recent Developments in Structure-Based Virtual Screening Approaches

Recent Trends and Applications of Molecular Modeling in GPCR–Ligand Recognition and Structure-Based Drug Design

Molecular Modeling Applied to Nucleic Acid-Based Molecule Development